The global immunohistochemistry market size was valued at USD 1.89 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 8.4% from 2022 to 2030. Increasing implementation of automation and machine learning in IHC, coupled with the introduction of technologically advanced Immunohistochemistry (IHC) solutions, is expected to significantly drive the market over the forecast period. Advancements in IHC protocols have boosted its demand to a significant level in disease diagnosis. In addition, the rise in product approvals and the launch of technologically advanced IHC systems for disease diagnosis are further propelling the market growth.
For instance, in August 2021, the FDA approved Roche’s VENTANA MMR RxDx Panel to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy. Companies continue to launch novel products to strengthen their market position, which leads to revenue generation. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit to detect and profile biomarkers and cell populations in tissue-based research. This kit can be utilized in combination with other detection kits, expanding the multiplexing capacity of in situ hybridization andIHC. The immunohistochemistry technology is limited to single parametric evaluations of a sample.
Newer techniques, such as multiplexed IHC, however, allow multiparametric and detailed analysis from a single tissue segment by utilizing advanced methods of mass spectrometric detection. Multiplexed IHC helps address the technical challenges posed by the labeled fluorescence detection-based method, thereby spurring the market revenue. The growing elderly population in both developed and emerging nations would favorably impact the market. The frequency of age-related disorders is expected to rise dramatically as the global geriatric population grows significantly. RT-PCR, IHC, and an electron microscope were used to detect the virus, indicating that the effect of SARS-CoV-2 is not limited to the lungs.
The antibodies segment dominated the market in 2021 and accounted for the largest share of more than 40.5% of the global revenue owing to the vital usage of antibodies in disease diagnosis and drug testing. The monoclonal antibodies and antibody-related products, such as Fc-fusion, antibody fragments, and antibody-drug conjugates have become the dominating product class in terms of usage rate. The antibodies are applied across a wide range of applications, such as pathology, neuropathology, and hematopathology. The kits segment is anticipated to expand at the fastest CAGR during the forecast period.
The use of kits reduces a lot of effort during the IHC procedure as it eliminates the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample. The compact nature and ease of use offered by the products under this segment are expected to drive the segment. IHC kits are commonly utilized in academic institutions and research laboratories that require these products in small quantities for carrying out research. Thus, a rising number of research programs that involve the use of IHC assays are contributing to the segment growth.
Based on applications, the global market has been further bifurcated into diagnostics and drug testing segments. The diagnostics application segment accounted for the largest revenue share of more than 69. 00% in 2021 and is anticipated to maintain its lead over the forecast period. Immunohistochemistry tests are widely used for the diagnosis of a wide range of chronic conditions, such as cancer, cardiovascular diseases, infectious diseases, diabetes mellitus, autoimmune diseases, and nephrological diseases. Furthermore, the growing prevalence of chronic diseases is anticipated to drive the diagnostics segment.
According to the data published by the American Cancer Society, around 1.9 million new cancer cases are expected to be reported in the U.S. in 2021. With a rise in the number of cancer cases, the need for IHC techniques for rapid and efficient diagnosis is high. Thus, the rising R&D activities by pharmaceutical companies for the research and development of innovative drugs are anticipated to increase the demand for IHC solutions and drive the segment. For instance, in July 2021, NHS England declared a novel innovative medicine fund to accelerate the research & development of new drugs.
Based on end-uses, the global market has been further sub-segmented into hospitals & diagnostic laboratories, research institutes, and others. In 2021, the hospitals and diagnostic laboratories segment dominated the market and accounted for the largest share of more than 70.5% of the overall revenue. This growth was attributed to the high volume of IHC tests carried out in hospital settings. Furthermore, with the constant changes in the healthcare industry, the need for hospitals with advanced facilities has also increased. This, in turn, is also expected to augment the revenue flow in this segment.
Research institutes are expected to register a lucrative CAGR during the forecast period. This is because the technique offers several advantages over conventionally used staining techniques in pharmaceutical R&D. For instance, a human-specific IHC-approved VISTA rabbit monoclonal antibody, manufactured by Cell Signaling Technology, is available for biomedical research use. The growth can be also attributed to the wide adoption of IHC techniques in drug testing by research institutes. The technique allows the evaluation of biomarker distribution and localization and different protein expressions in varied biological tissue sections, which is conducted in research settings. Research institutes play a significant role by applying IHC techniques in drug development for the evaluation of drug efficacy tests.
Based on regions, the global market has been further sub-categorized into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2021 and accounted for the largest share of more than 38.5% of the global revenue. Key factors contributing to the regional market growth include the presence of major market players, easy availability of IHC solutions, higher adoption of technologically advanced IHC instruments, and entry of newer IHC solutions.
For instance, in June 2021, PathAI, a U.S.-based developer of AI-powered technology for pathological applications, showcased a machine learning-based quality control tool, designed for HER2 testing in breast cancer, at the American society of clinical oncology virtual scientific program 2021. Asia Pacific is expected to witness the fastest CAGR during the forecast period. This is primarily due to the expansion of the geographic footprint of the global players in the Asian markets. Furthermore, a large patient pool in countries, such as India and China, provides a large number of clinical subjects to carry out IHC R&D assays, resulting in revenue growth.
With the rising demand for IHC assays in cancer diagnostics, the key players are undertaking various strategic initiatives in the field of IHC, including new product launches, mergers & acquisitions, and regional expansion, to meet the market needs. For instance, in January 2021, Biocare medical LLC launched the ONCORE Pro, a fully automated in vitro diagnostic benchtop system for In-situ Hybridization (ISH) and IHC applications. In January 2021, Abcam and Shuwen Biotech (Shuwen) entered into a strategic alliance for developing and commercializing Companion Diagnostics (CDx). Under the agreement, Abcam is providing recombinant rabbit monoclonal antibodies to Shuwen Biotech for further immunohistochemical verification. Some prominent players in the global immunohistochemistry market include:
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Merck KGaA
Danaher Corporation
Perkinelmer, Inc.
Bio-Rad Laboratories, Inc.
Cell Signaling Technology, Inc.
Bio SB
Agilent Technologies, Inc.
Abcam plc.
Report Attribute |
Details |
Market size value in 2022 |
USD 2.06 billion |
Revenue forecast in 2030 |
USD 3.92 billion |
Growth rate |
CAGR of 8.4% from 2021 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, end-use, and region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Russia; Japan; China; India; Australia; Singapore; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; PerkinElmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Bio SB; Abcam plc.; Agilent Technologies, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global immunohistochemistry market report on the basis of product, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Antibodies
Primary Antibodies
Secondary Antibodies
Equipment
Slide Staining System
Tissue Microarrays
Tissue Processing Systems
Slide Scanners
Others
Reagents
Histological stains
Blocking Sera and Reagents
Chromogenic Substrates
Fixation Reagents
Stabilizers
Organic Solvents
Proteolytic Enzymes
Diluents
Kits
IHC Kits for Human Tissue
IHC Kits for Animal Tissue
Application Outlook (Revenue, USD Million, 2018 - 2030)
Diagnostics
Cancer
Infectious Diseases
Cardiovascular Diseases
Autoimmune Diseases
Diabetes Mellitus
Nephrological Diseases
Drug Testing
Forensic applications
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals & Diagnostic Laboratories
Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
South Korea
Australia
Singapore
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global immunohistochemistry market size was estimated at USD1.89 billion in 2021 and is expected to reach USD 2.06 billion in 2022.
b. The global immunohistochemistry market is expected to grow at a compound annual growth rate of 8.4% from 2022 to 2030 to reach USD 3.92 billion by 2030.
b. Antibodies dominated the immunohistochemistry (IHC) market with a share of 40.7% in 2021. This is attributable to their continuous usage in IHC procedures for disease diagnosis and drug testing.
b. Some key players operating in the IHC market include Abcam plc; Agilent Technologies; Bio SB; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; F. Hoffmann-La Roche AG; Merck KGaA; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc.
b. Key factors that are driving the IHC market growth include the emergence of multiplexed immunohistochemistry, the implementation of automation and machine learning in IHC, and an increase in the prevalence of cancer.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.